10-Q 2026-07-30 ↗ compared with the reference 10-K 10-K 2026-02-04 ↗
Technical events and factor profile →
Regeneron Pharmaceuticals warns of AI-generated errors and biased outputs, and faces increased tariffs on imports from 60 countries.
| After the 10-Q | 1 session | 5 sessions | 20 sessions |
|---|---|---|---|
| REGN | +6.2% | +10.5% | +17.3% |
| Nasdaq-100 (QQQ) | +3.3% | +8.4% | +7.5% |
| Difference | +2.9% | +2.1% | +9.8% |
From the close before the filing. Historical data, not a prediction.
We are increasingly utilizing AI-based solutions in various facets of our research, development, and other operations and continue to explore further use cases for AI. AI systems may generate inaccurate, incomplete, misleading, or biased outputs that may not be readily detectable by users, or may produce unreliable outputs over time. Reliance on such outputs could result in errors, inefficiencies, compliance issues, or other adverse consequences. Employee use of unapproved AI tools could create ungoverned data flows, unmonitored compliance gaps, and data protection risks that are not visible until an adverse event occurs. In addition, the increasing use of agentic and autonomous AI systems may create additional operational, cybersecurity, compliance, and data protection risks. Failures in the design, governance, or monitoring of such systems could result in unauthorized actions, inaccurate and/or biased outputs, disruption of business processes, or unauthorized access to sensitive information.
| Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | |
|---|---|---|---|---|---|
| Revenue | $4.3B | $3.6B | $3.9B | $3.8B | $3.7B |
| YoY growth | +16.7% | +19.0% | +2.5% | +0.9% | +3.6% |
| Gross margin | — | — | — | — | — |
| Operating margin | 30.1% | 17.8% | 22.7% | 27.3% | 29.4% |
| Net income | $1.3B | $727M | $845M | $1.5B | $1.4B |
| Diluted EPS | 12.23 | 6.75 | 7.78 | 13.62 | 12.81 |
XBRL data filed with the SEC. The fourth fiscal quarter is calculated as the full year minus the previous three quarters.
0 = the lowest in the universe, 100 = the highest. It describes how the stock has behaved, not whether to buy or sell it. Screen stocks by factors
Similar than in the previous 10-Q (2026-04-29: +5, -0 points)
10-Q of 2026-07-30 · 14.1% positive sentences, 11.6% negative · 199 sentences analysed
Index from −100 to +100 calculated with FinBERT on the results discussion (MD&A). The change matters more than the level: some sectors always sound more cautious.
| Bridgewater Associates · Ray Dalio
held since Q3 2023 or earlier |
0.1% | $32.0M | +126% |
Weight in each fund's portfolio and change vs. the previous quarter, from its latest 13F.
All material events for REGN →
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $361K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $354K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $296K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $292K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $218K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $214K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $207K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $173K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $167K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $163K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $147K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $98K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $94K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $81K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $56K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $51K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $42K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $39K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $30K | SEC ↗ |
| 2026-10-14 | MURPHY ANDREW J · Officer | Sell (10b5-1 plan) | $26K | SEC ↗ |
Source: SEC EDGAR. Automatic comparison of the risk factors section; it may contain extraction errors. Always check the original document. For information purposes only; not investment advice.